World-class biologics research and development facility in Hubli-Dharwad specializing in biosimilars, monoclonal antibodies, fusion proteins, metabolic pathway engineering, and cGMP pilot manufacturing for clinical trials and commercial applications
Biologics now constitute about 27% of prescription pharma sales, while biologics share within the top 100 drugs is ~50%! – showcasing the effectiveness of these drugs, whose target markets are oncology, autoimmune disorders, hematology and diabetes.
Growth Opportunity:
Within this, biosimilars opportunity is the next growth driver for the generic market.
Shilpa Medicare Ltd, through its Biologics Research & Development centre in Hubli-Dharwad area is well poised to tap into this unprecedented biologics opportunity with cutting-edge technology and world-class infrastructure.
Cancer therapeutics and targeted treatments
Immune system disorder treatments
Blood disorder therapeutics
Metabolic disorder management
Advanced platforms for cell line development and biological activity assessment
High throughput fermentation units enabling rapid process optimization
Conventional and continuous chromatography units for protein purification
High-end, high throughput analytical capabilities for comprehensive characterization
Complete formulation development engine for drug product optimization
State-of-the-art QC systems ensuring product safety and efficacy
The technologies developed at this unit have been recognized by the Department of Biotechnology, Government of India as amongst the most innovative in the country.
The Biologics SBU is part funded by the National Biopharma Mission to setup a world-class, flexible cGMP Biologics Pilot facility catering to Clinical Grade Drug Substance and Drug Product requirements for Human Clinical Trials and early commercial batches.
This new facility helps bridge the gap between R&D and large scale GMP manufacturing requirements of most biopharma customers, ensuring seamless transition from development to commercial production.
We actively look for strategic collaborations to accelerate biologics innovation:
Strategic Research & Development and commercialization partnerships with global pharmaceutical companies.
Start-ups interested in co-developing their leads & molecules with our advanced platform.
Flexible cGMP biologics pilot facility
Drug substance & product for human trials
Meets NBM program requirements
